Loading...

Εκπαιδευτικά προγράμματα

Καταχωρήθηκε: Δευτέρα 03 Σεπ 2018
The antiviral prophylaxis for cytomegalovirus infection in allogeneic  hematopoietic cell transplantation was reviewed. Prophylaxis reduse CMV  reactivation and disease but has little effect on OS in older studies,  except the newly published letermovir study. We discussed our current practice. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
Καταχωρήθηκε: Δευτέρα 27 Αύγ 2018
A transplantational research project showing that the combined Tx of CBU and  multiple allogeneic progenitors may facilitate early engraftment without  affecting the long term engraftment of the single CBU. Presenter:Prof.Spyridonidis Participants: Dr.Liga, Dr.Spyridis, Dr.Aggelinas
Καταχωρήθηκε: Δευτέρα 27 Αύγ 2018
We discussed an excellent article published in NEJM regarding the clinical value of PDL1 expression. Presenter:Prof.Spyridonidis Participants: Dr.Liga, Dr.Spyridis, Dr.Aggelinas
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
The significance of HHV6 viremia was discussed. Presenter:Prof.Spyridonidis Participants:Dr.Liga, Dr.Spyridis, Dr.Aggelinas
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
A study entitled "Graft-versus-host disease in recipients of male  unrelated donor compared with parous female sibling donor transplants"  was presented. This was  a retrospective cohort study in adults with acute myeloid  leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome, who  underwent T-cell replete HCT from these 2 donor types (parous female  sibling...
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
A retrospective study  comparing sibling vs PTCY haplo was presented Patient age, 18 to 54 years: comparable survival after transplants from  an HLA-matched sibling and a haploidentical sibling. Patient age, 55 to 76 years: better survival after transplants from an  HLA-matched sibling compared with offspring. Presenter: Prof.Spyridonidis Participants: Dr.Liga, Dr.Spyridis,...
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
The use of defibrotide in blood and marrow transplantation was discussed. Presenter: Prof. Spyridonidis Participants: Dr.Liga, Dr.Spyridis, Dr.Aggelinas
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
A paper in BV entitled "Prediction of cardiovascular disease among  hematopoietic cell transplantation survivors" was presented. Presenter: Prof. Spyridonidis Participants: Dr.Liga, Dr Spyridis, Dr. Aggelinas
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
Based on a case of our unit we discussed "Outcomes of patients who  developed subsequent solid cancer after hematopoietic cell  transplantation" Presenter:Prof.Spyridonidis Participants:Dr.Liga, Dr.Spyridis, Dr.Aggelinas
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
A paper published in Blood Advances and entitled "How ibrutinib, a  B-cell malignancy drug, became an FDA-approved second-line therapy for  steroid-resistant chronic GVHD" was presented. Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Spyridis, Dr Aggelinas
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
An excellent review/focus from R Storb. His fazit, " Therefore, faced with the choice of an HLA-identical sibling marrow  graft or even an alternative donor graft vs immunosuppression, many  patients should be counseled in favor of marrow transplantation as  first-line therapy."   Presenter:Prof. Spyridonidis Participants:Dr. Liga, Dr.Spyridis, Dr Aggelinas
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
A recent study published in Blood advances "Evaluation of induction  chemotherapies after hypomethylating agent failure in myelodysplastic  syndromes and acute myeloid leukemia" was presented. Induction led to response in 41% and 32%, survival of 10.8 and 6 months,  and transplant in 40% and 42% of responders in MDS...
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
We discussed the emerging data of the importance of asparaginase in the  treatment of ALL. We discussed the potential toxicities and how we can  manage them. The time point of application plays after cheotherpay is of  major importance. Monitoring for pancreatitis and bleeding should be  done routinely. Presenter: Prof....
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
We discussed the current literature regarding the role of allo HCT in  the era of BV and PD1 blockade for HD. Patients with cHL who are ineligible for auto-HCT or relapse after  auto-HCT have historically had a poor prognosis with a median survival  of 2 years or...
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
A patient with JAkavi resistant LF who was referred to our unit was  presented and discussed. We also presented the current How I treat paper  form Blood. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
2018-W15 : Update on CLL treatment algorithm.
The Oncopedia 2018 update on CLL treatment algorithm has presetend and  discussed. Presenter: Prof. Spyridondis Partricpants: Dr Liga, Dr Spyridis, Dr Aggelinas  
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
Presenter: Prof. Spyridonidis Participants:Dr Liga, Dr Spyridis, Dr Aggelinas   Main studies in newly diagnosed MM (NDMM) presented in 23. Congress, European Hematology Association (EHA), Stockholm, Sweden.   ALCYONE NDMM, >65y, auto non-eligible Daratumumab (D) plus Bortezomib-Melphalan-Prednison (VMP) vs VMP more CR, PFS nr vs 20,4 Mo, no problems with addtion of Daratumumab  GIMEMA  Phase-3, NDMM  Bortezomib, Thalidomid-Dexamethason (VTD) vs TD, pre...
Καταχωρήθηκε: Πέμπτη 09 Αύγ 2018
Presenter: Dr Liga Participants:Prof. Spyridonidis, Prof. Marangos, Dr Spyridis, Dr Aggelinas
Καταχωρήθηκε: Τρίτη 31 Ιούλ 2018
The update of WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES was presented. Presenter: Prof:Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
Καταχωρήθηκε: Τετάρτη 25 Ιούλ 2018
Goal of the educational session is to understand the role of DPB1 mismatched in allo Tx. We discussed their level of expression and  their alloreactivity as is scored in the TCE algorithm. We also discussed a new proposed methodology which defines the DPB1 alloreactivity...
Βρέθηκαν 279 αποτελέσματα. Σελίδα 8 από 14
Σελίδα << < [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] > >>
 

 

Τηλέφωνα Επικοινωνίας:

 

Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) 
Fax : 2613 604066,
email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gr
email (για θέματα κλινικών μελετών) : gcppatras@gmail.com
Μονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261
Γραφείο Ιατρών: 2613 604064, 2613 604065,
Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)

 

βρείτε μας στο χάρτη

 

Login / Sitemap

 

© Copyright 2015 - 2021 Μονάδα Μεταμόσχευσης Μυελού των Οστών Πάτρας